Alembic Pharmaceuticals receives USFDA Final Approval for Fulvestrant Injection
Alembic Pharmaceuticals Ltd has received final approval from the US Food & Drug Administration for its Abbreviated New Drug Application, Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per SingleDose Prefilled Syringe.
Alembic Pharmaceuticals Limited Alembic Pharmaceuticals Astrazeneca Pharmaceuticals Us Food Drug Administration Pharmaceuticals Limited Drug Administration
Source: equitybulls.com